Chimeric Therapeutics
June 18, 2025
Company Presentation
Cell and Gene Therapy and Genome Editing
153A
Chimeric Therapeutics is a clinical stage cell therapy company. CHM has four phase 1 clinical trials across three assets. CHM is proud to be developing two Auto-CAR-Ts, one for GI cancers and another for Glioblastoma. CHM also has an off the shelf ALLO NK platform currently being tested in a frontline setting in AML.
Company HQ City:
Carlton
Company HQ State:
Victoria
Company HQ Country:
Australia
Year Founded:
2020
Lead Product in Development:
CHM CDH17
CEO
Dr Rebecca McQualter
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
1
Exchange
ASX
Ticker
ASX:CHM
When you expect your next catalyst update?
CHM CDH17 Phase 1 read out Dose level 2
What is your next catalyst (value inflection) update?
June 2025
Website
chimerictherapeutics.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}